This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
Efficacy & SafetyAboutEfficacy & SafetyPatient SupportAboutAboutCommitment to the GH CommunityIndication & DosingIndication & DosingAdultsChildren

Menu

Close

Efficacy & SafetyAdultAdult Growth Hormone DeficiencyChildrenSmall for Gestational AgeTurner SyndromePrader-Willi SyndromeChronic Renal Insufficiency
Pediatric Growth Hormone Deficiency
Idiopathic Short Stature
DevicesPenPen PresentationHow to Use the PenGoQuickGoQuick PresentationHow to Use GoQuickPatient SupportPatient SupportGroAssistBranded Patient Information LeafletsEducational SupportEducational SupportPrescribing InformationWebinarsEventsMaterialsVideos

Prescribing Information

SPI of Somatropin for Injection I.P. GENOTROPIN®

    

Composition:
Recombinant Somatotropin I.P. (Sterile, Lyophilized Powder) for solution for subcutaneous Injection; 5.3 mg (16IU) and 12 mg (36IU) with sterile diluents (m-Cresol-Mannitol-Water) for injection.
Recombinant Somatotropin I.P. (Sterile, Lyophilized Powder); 12 mg (36IU) with sterile diluents (m-Cresol-Mannitol-Water) for injection. (GoQuick).
Recombinant Somatotropin I.P. (Sterile, Lyophilized Powder) for solution for subcutaneous Injection; 5.3 mg (16 IU) with sterile diluents (m-Cresol-Mannitol-Water) for injection (GoQuick)

    

Indications: for treatment of children with growth disturbance due to, Short stature due to inadequate or failed secretion of pitutory growth hormone; Turner syndrome; Chronic renal insufficiency; Born small for gestational age; For improvement of body composition in children with Prader-Willi syndrome; For replacement therapy in adults with growth hormone deficiency;For the treatment of idiopathic short stature.

Contraindications: Any evidence of neoplastic activity, anti-tumor therapy, acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure and hypersensitivity to active substance or any of the excipients.

Warnings and Precautions: In the case of myalgia or disproportionate pain at injection site, myositis should be considered and if confirmed, a Genotropin presentation without m-cresol should be used. Treatment should be interruptedin patients with Prader-Willi syndrome taking Genotropin who show signs of upper airway obstruction Genotropin reduces insulin sensitivity and therefore patients should be observed for evidence of glucose intolerance.In rare cases, therapy with Genotropin may produce sufficient glucose intolerance to meet the diagnosis criteria for Type 2 diabetes mellitus. The risk of developing diabetes during treatment with Genotropin is greatest in those patients with other risk factors for Type 2 diabetes mellitus, such as obesity, family history of diabetes, treatment with steroids, or prior impaired glucose tolerance. Dose adjustment of anti-diabetic therapy may be required in patients with preexisting diabetes mellitus who are on Genotropin. It is advisable test thyroid function shortly after the start of treatment with Genotropin, and after dose adjustments. Hypoadrenalism: Introduction of somatropin treatment may result in inhibition of 1113HSD-1 and reduced serum cortisol concentrations. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and gluoocorticoid replacement may be required. In addition, patients treated with glucooorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment In patients with hypopituitarism on standard replacement therapy, the potential effect of growth hormone treatment on thyroid function must be closely monitored.Benign intracranial hypertension, Leukaemia, Antibodies, Elderly patients, Acute critical illness In all patients developing other or similar acute critical illness, the possible benefit of treatment with Genotropin must be weighed against the potential risk involvedUse with oral oestrogen therapy: If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues
oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects. In case of severe or recurrent headache, visual problems, nausea and/or vomiting, a fundoscopy for papilloedema is recommended. Progression of scoliosis can occur in patients who experienoe rapid growth. Genotropin should discontinue at renal transplantation. Genotropin is ineffective for growth promotion in children with closed epiphyses. Side Effects: Injection site reaction. Arthralgia, Myalgia, Peripheral oedema, Type 2 diabetes mellitus, Paraesthesia, Benign intracranial hypertension, Leukemia. In children, such as adverse effects are uncommon.

Dosage: The dosage and administration schedule should be individualized, drug should be given subcutaneously. In growth hormone deficiency in children, daily dose of 0.025 - 0.035 mg/kg body weight (0.07 - 0.1 O IU/kg) or 0.7 - 1.0 mg/m2 body surface area ( 2.1 - 3.0 IU/m2) is recommended. In Turner syndrome and chronic renal insufficiency, the daily dose of 0.045 - 0.050 mg/kg body weight (0.14 IU/kg) or 1.4 mg/m2 body surface area (4.3 IU/m2) is recommended. In Prader-Willi syndrome in children, the daily dose of 0.035 mg/kg body weight (0.10 IU/kg) or 1.0 mg/m2 body surface area (3.0 IU/m2) is recommended. In small for gestational age, the daily dose of 0.035 mg/kg body weight (0.10 - 0.20 IU/kg) or 1.0 mg/m2 body surface area (3.0 - 6.0 IU/m2} is recommended. In idiopathic short stature, the recommended dose of Genotropin is up to 0.067 mg/kg body weight (0.20 IU/kg) or upto 2.0 mg/m2 body surface area (6.0 IU/m2). Dosage Recommendations for Adult Patients with Growth Hormone Deficiency: The recommended starting dose is 0.15 to 0.30 mg (0.45 to 0.90 IU) per day. The final dose should be individually titrated as needed with respect to age and gender. The daily maintenance dose seldom exceeds 1.3 mg (4 IU) per day. Clinical response, side effects, and determination of IGF-1 in serum may be used as guidance for dose titration.Genotropin is not to be injected intravenously. Genotropin may be given in the thigh, buttocks or abdomen. The site of injection should be rotated daily to help prevent lipoatrophy.

Adapted from
Local Product document Genotropin 5.3mg and 12 mg formulation LPDSOM052020.
Local Product Document: Somatropin for Injection I.P.Genotropin
® GoQuick  12 mg LPDSOM052020.
Local Product Document: Somatropin for Injection I.P.Genotropin
® GoQuick  5.3 mg LPDSOM052020
® Trademark Proprietor: Pfizer Health AB. Licensed User: Pfizer Products India Private Limited, India

   

   

PP-GEN-IND-0678 July 2022

Educational Support

   

Efficacy & Safety

Proven in different health conditions2-5

Learn moreLoading
Devices

Simplicity and flexibility in administration1

Learn moreLoading
Patient Support

Multiple support material

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-GEN-IND-0678

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​